{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:53:23Z","timestamp":1790254403938,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T00:00:00Z","timestamp":1638835200000},"content-version":"vor","delay-in-days":1594,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cellular therapies and other regenerative medicines are emerging as potentially transformative additions to modern medicine, but likely at a staggering financial cost. Public health care systems\u2019 budgets are already strained by growing and aging populations, and many private insurer's budgets are equally stretched. The current systems that most payers employ to manage their cash flow are not structured to absorb a sudden onslaught of very expensive prescriptions for a large portion of their covered population. Despite this, developers of new regenerative medicines tend to focus on the demands of regulators, not payers, in order to be compliant throughout the clinical trials phases, and to develop a product that ultimately will be approvable. It is not advisable to assume that an approved product will automatically become a reimbursed product, as examples from current practice in hematopoietic stem cell transplantation in the U.S. demonstrate; similarly, in Europe numerous Advanced-therapy Medicinal Products achieved market authorization but failed to secure reimbursement (e.g., Glybera, Provenge, ChondroCelect, MACI). There are however strategies and approaches that developers can employ throughout clinical development, in order to generate clinical and health economic data which will be necessary to demonstrate the value proposition of the new product and help ensure market access for patients; furthermore, performance based managed entry agreements coupled with post-launch evidence generation can help overcome challenges around product uncertainty at launch and reduce market access delays.<\/jats:p>","DOI":"10.1002\/sctm.16-0487","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T12:25:19Z","timestamp":1501158319000},"page":"1723-1729","source":"Crossref","is-referenced-by-count":53,"title":["Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access"],"prefix":"10.1093","volume":"6","author":[{"given":"Dawn","family":"Driscoll","sequence":"first","affiliation":[{"name":"a DCi Biotech Inc. and DCi Biotech Pty Ltd., Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Farnia","sequence":"additional","affiliation":[{"name":"b American Society for Blood and Marrow Transplantation, Arlington Heights, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panos","family":"Kefalas","sequence":"additional","affiliation":[{"name":"c Cell and Gene Therapy Catapult Limited, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"d Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"2022022809522729600_R1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.2006.09.6081","article-title":"Cost of cancer care: Issues and implications","volume":"25","author":"Meropol","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022022809522729600_R2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":"Projections of the cost of cancer care in the United States: 2010\u20132020","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2022022809522729600_R3","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jama.2010.283","article-title":"Cancer's next frontier: Addressing high and increasing costs","volume":"303","author":"Elkin","year":"2010","journal-title":"JAMA"},{"key":"2022022809522729600_R4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1056\/NEJMp1512297","article-title":"Asymmetric thinking about return on investment","volume":"374","author":"Asch","year":"2016","journal-title":"N Engl J Med"},{"key":"2022022809522729600_R5","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med."},{"key":"2022022809522729600_R6","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.bbmt.2015.04.014","article-title":"Goals for pay for performance in hematopoietic cell transplantation: A primer","volume":"21","author":"LeMaistre","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809522729600_R7","first-page":"1","article-title":"Organ and tissue transplant cost estimates and discussion. 2011 U.S","author":"Bentley","year":"2014","journal-title":"Milliman Research Report"},{"key":"2022022809522729600_R8","author":"Stranges"},{"key":"2022022809522729600_R9","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.bbmt.2014.07.007","article-title":"Optimal benefits for hematopoietic stem cell transplantation: A consensus opinion","volume":"20","author":"Maziarz","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809522729600_R10","first-page":"11","volume-title":"The business of cellular therapy and hematopoietic stem cell transplantation","author":"Appel","year":"2015"},{"key":"2022022809522729600_R11","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.bbmt.2015.04.014","article-title":"Standardization of terminology for episodes of hematopoietic stem cell patient transplant care","volume":"21","author":"LeMaistre","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809522729600_R12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11899-013-0191-0","article-title":"Impact of the affordable care act on stem cell transplantation","volume":"9","author":"Farnia","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"2022022809522729600_R13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02196966","article-title":"Oregon's experiment","volume":"1","author":"Brannigan","year":"1993","journal-title":"Health Care Anal"},{"key":"2022022809522729600_R14","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.bbmt.2016.05.008","article-title":"Financial hardship and patient-reported outcomes after hematopoietic cell transplantation","volume":"22","author":"Abel","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022022809522729600_R15","doi-asserted-by":"publisher","first-page":"29321","DOI":"10.3402\/jmahp.v3","article-title":"Reimbursement of licensed cell and gene therapies across the major European healthcare markets","volume":"3","author":"Jorgensen","year":"2015","journal-title":"J Mark Access Health Policy"},{"key":"2022022809522729600_R16","doi-asserted-by":"publisher","first-page":"24966","DOI":"10.3402\/jmahp.v3","article-title":"A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments","volume":"3","author":"Massetti","year":"2015","journal-title":"J Mark Access Health Policy."},{"key":"2022022809522729600_R17"},{"key":"2022022809522729600_R18"},{"key":"2022022809522729600_R19"},{"key":"2022022809522729600_R20"},{"key":"2022022809522729600_R21"},{"key":"2022022809522729600_R22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbmt.2005.07.014","article-title":"the new apheresis and blood and marrow transplantation\u2013related current procedural terminology codes for payment of apheresis and blood and marrow transplantation services","volume":"11","author":"Gajewski","year":"2005","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsctm.16-0487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sctm.16-0487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/sctm.16-0487","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/8\/1723\/42633209\/stcltm_6_8_1723.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/6\/8\/1723\/42633209\/stcltm_6_8_1723.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T10:07:44Z","timestamp":1646042864000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/6\/8\/1723\/6454760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,7,27]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/sctm.16-0487","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8,1]]},"published":{"date-parts":[[2017,7,27]]}}}